Purpose: Advanced/recurrent cervical cancer has limited therapeutic options, with a median progression-free survival after the failure of systemic treatments ranging between 3.5 and 4.5 months. Here, we reported our preliminary experience in the use of BYL719 (alpelisib) in advanced/recurrent cervical cancer after failure of at least 2 lines of treatment. The Istituto Nazionale dei Tumori di Milano approved this investigation.
Methods: From April 2020 to September 2020, 17 consecutive patients with recurrent cervical cancer had Next Generation Sequencing (NGS). Of these, six patients harboring the PIK3CA mutation were included in the study. All patients had been treated with at least 2 previous lines of systemic treatment: 3 patients received >2 prior lines of treatment in the recurrent or metastatic setting; 60% had received prior bevacizumab in combination with chemotherapy. All patients started alpelisib at the daily dosage of 300 mg.
Results: Investigator-assessed confirmed objective response rate (ORR) was 33%. The disease control rate (DCR) was 100%. According to RECIST 1.1, two patients had a partial response (PR), and four patients had stable disease (SD). No complete response was observed. The mean duration of response (DOR) was 11.5 (SD 3.75) months; five patients had PR lasting for >9 months. One patient stopped the treatment at 0.82 months due to the onset of a grade 2 adverse event (AE) (skin rash). Grade 3 treatment-related AEs included: lymphoedema (n = 1, 17%) and rash (n = 1, 17%). No treatment-related grade 4-5 AEs occurred.
Conclusions: Our preliminary data highlighted a high level of efficacy in this setting of patients. Further trials are needed to assess the safety and effectiveness of alpelisib in PIK3CA-mutated recurrent/advanced cervical cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03008916211073621 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.
Cancer Causes Control
January 2025
Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Purpose: Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.
View Article and Find Full Text PDFHigh unmet needs for cervical cancer screening among women living with HIV in six African countries: A population-based study.
Int J STD AIDS
January 2025
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Background: Cisgender women living with HIV (WLWH) are disproportionately impacted by cervical cancer. Nevertheless, disparities in uptake and implementation of cervical cancer services persist in sub-Saharan Africa, where population-level estimates of screening coverage remain scarce.
Methods: We pooled data from nationally representative Population-based HIV Impact Assessment (PHIA) surveys conducted in Ethiopia, Malawi, Rwanda, Tanzania, Zambia, and Zimbabwe (2015-2019).
Incredible use of plant-derived bioactives as anticancer agents.
RSC Adv
January 2025
Department of Pharmaceutical Sciences, Maharshi Dayanand University Rohtak 124001 India
Cancer is a major global concern. Despite considerable advancements in cancer therapy and control, there are still large gaps and requirements for development. In recent years, various naturally occurring anticancer drugs have been derived from natural resources, such as alkaloids, glycosides, terpenes, terpenoids, flavones, and polyphenols.
View Article and Find Full Text PDFAn Unexpected Case of Clear Cell Adenocarcinoma of the Cervix in a Non-Diethylstilbestrol-Exposed Postmenopausal Woman.
Cureus
December 2024
Department of Family Medicine, Corewell Health Beaumont Grosse Pointe Hospital, Roseville, USA.
Clear cell adenocarcinoma of the cervix (CCAC) is a rare subtype of cervical adenocarcinoma. It has been linked to intrauterine exposure to diethylstilbestrol (DES) but can happen in non-DES-exposed patients, albeit less commonly. Presentation is largely vaginal bleeding, emphasizing the importance of considering CCAC in the differential of abnormal vaginal bleeding despite the tumor's rarity.
View Article and Find Full Text PDFKnowledge, Attitudes, and Perceptions of African Parents in New Zealand Towards the Human Papillomavirus Vaccine.
Cureus
December 2024
Research, Oceania University of Medicine, Apia, WSM.
Introduction Human papillomavirus (HPV) is a well-documented cause of cervical cancer, leading to significant mortality that may be decreased through screening and the administration of HPV vaccination. Our understanding of New Zealand immigrants' knowledge, attitudes, and perceptions of the HPV vaccine is limited. Preliminary research shows that immigrants have low knowledge and negative perceptions of the HPV vaccine and that cervical cancer and HPV awareness was low among African parents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!